The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
AstraZeneca shares drop amid Chinese investigation into sales practices
AstraZeneca's shares fell 8.4% on the London Stock Exchange amid concerns over a Chinese investigation into alleged aggressive sales tactics for its oncology drugs, Tagrisso and Imjudo. The company's local president, Leon Wang, is under investigation, signaling increased scrutiny from Beijing. Despite the turmoil, AstraZeneca aims for $80 billion in sales by 2030, up from $45.8 billion in 2023, with plans to launch 20 new drugs by the decade's end.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.